From 1 January 2011 to 31 December 2012, a significantly higher proportion of people with type 2 diabetes were receiving treatment with non-secretagogues (58.9%) or insulin (18.7%), but fewer were being treated with secretagogues (22.4%). This evidence concerns the gene INS and type 2 diabetes mellitus.